SCIENTIFIC POSTER 2016_Outcome of IVTY of Ocriplasmin for Symptomatic Vitreomacular Adhesion Mostafa Elgohary


To evaluate the rate of release of vitreomacular adhesion (VMA), anatomical changes and visual outcome following intravitreal ocriplasmin injection for the treatment of symptomatic VMA with and without full-thickness macular hole (FTMH).


This is a retrospective, interventional, case-series of 12 eyes of 11 consecutive patients who received intravitreal injection of 0.125mg ocriplasmin (Jetrea; Alcon). Assessment included visual acuity, fundus examination and spectral domain optical coherence tomography at baseline and at each follow-up visit.


VMA release was achieved in 5 of 12 eyes (41.6%) by day 28, and in 7 of 12 eyes (58%) by day 136. Of the 2 eyes that had a FTMH, none achieved closure. Three eyes (25%) underwent pars plana vitrectomy and the 2 FTMHs closed after surgery. Outer retinal changes included the development of subfoveal fluid in 7 eyes (58%) and loss of the ellipsoid zone in 6 eyes (50%) but all resolved by 3 months. In those with VMA release, distortion and diplopia reduced in n (%) and visual improvement of >= 2 lines occurred in n (%). The median VA was …. & …. for pre and post injection, respectively (include p of Wilcoxon ranksum for pre and post VA).


Intravitreal injection of ocriplasmin achieved successful release of VMA and improvement in visual acuity in the majority of patients and was associated with transient outer retinal changes. We had only 2 patients with FTMH and therefore could not make definite conclusion regarding the outcome of ocriplasmin use in those patients.

Contact Details:

Cell Phone: +447939274217

Mostafa Elgohary